Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.